Close Menu

cancer of unknown primary

The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.

As part of a collaboration with Freenome, Institut Curie will look for correlations between circulating biomarkers and human response to cancer immunotherapies.

The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications.

China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.

Pages